The Ghana Medical Trust Fund (GMTF) has begun strategic engagements aimed at ensuring that Ghanaians receive the right medication at the right time as part of a new health intervention initiative under the Fund.
On Wednesday, 10th December 2025, on the sidelines of the ongoing WHX Leaders Africa Summit in Accra, the Administrator of the Fund, Adjoa Obuobia Darko-Opoku, held discussions with a delegation from Pfizer, the American multinational pharmaceutical and biotechnology company, to explore potential areas of collaboration.
The meeting focused on how both institutions could partner to improve access to quality healthcare for Ghanaians, particularly within the framework of the Ghana Medical Trust Fund.
Ms. Darko-Opoku reaffirmed GMTF’s commitment to its four core pillars: providing financial assistance to approved beneficiaries accessing specialised medical care for chronic diseases; investing in medical equipment, infrastructure development, human resources, and research programmes; offering financial support for specialist medical training; and supporting research relevant to chronic disease care.
She noted that while these pillars remain central to the Fund’s mandate, ensuring that direct beneficiaries receive essential medicines promptly is also a top priority—making partnerships with reputable pharmaceutical companies such as Pfizer critical.
“The collaboration reflects GMTF’s goal to ensure that no Ghanaian is left behind due to cost, geography, or limited access to essential therapies. This marks a promising start to a long-term partnership between the Trust Fund and Pfizer, as we work together towards a Ghana where everyone can receive world-class care when they need it most,” she said.
The Pfizer delegation, led by Vice President, Access and Accord Lead, Abdelali Besri, expressed readiness to collaborate with the Trust Fund.
According to the delegation, the engagement aligns with Pfizer’s global efforts to expand access to healthcare. Through the Accord, Pfizer is offering its full portfolio of medicines and vaccines—over which it holds global rights—on a not-for-profit basis to people living in selected lower-income countries around the world.